澳大利亚已接种和未接种HPV疫苗女性的原发HPV检测与细胞学宫颈筛查比较:国家宫颈筛查计划的有效性与经济学评估
该分析采用HPV传播、疫苗接种、自然史和宫颈筛查模型,评估132种筛查策略的有效性与经济学效果。每5年原发HPV检测联合部分基因分型最为有效且具成本效益,预测使未接种队列宫颈癌发病率和死亡率分别降低31%和36%,接种队列分别降低24%和29%,并降低费用。
要点
- 每5年原发HPV检测联合部分基因分型是有效且具成本效益的筛查策略。
- 该策略预测未接种队列宫颈癌发病率和死亡率分别降低31%和36%。
- 接种队列宫颈癌发病率和死亡率分别降低24%和29%,费用降低可达26%。
核心结论
- 每5年原发HPV检测联合部分基因分型预测比现行每2年细胞学筛查更有效且可能节省成本,该结果支持澳大利亚国家宫颈筛查计划于2017年5月转为原发HPV检测联合部分基因分型。
研究设计与样本
- 采用HPV传播、疫苗接种、自然史和宫颈筛查模型,对132种筛查策略进行有效性建模和经济学评估,并同时考虑未接种和已接种疫苗队列。
主要发现
- 每5年HPV检测联合HPV16/18部分基因分型或细胞学联合检测的策略最为有效。
- 在纳入详细临床指南建议后,该策略预测未接种队列宫颈癌发病率和死亡率分别降低31%和36%。
- 该策略预测接种疫苗队列宫颈癌发病率和死亡率分别降低24%和29%。
- 与现行计划相比,该策略预测未接种队列费用降低可达19%,接种疫苗队列费用降低可达26%。
关键数值与推荐
- 现行国家宫颈筛查计划推荐18-69岁女性每2年进行细胞学筛查。
- 推荐采用原发HPV检测联合部分基因分型,HPV16/18阳性女性直接转诊阴道镜。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia's National Cervical Screening Program currently recommends cytological screening every 2 years for women aged 18-69 years. Human papillomavirus (HPV) vaccination was implemented in 2007 with high population coverage, and falls in high-grade lesions in young women have been reported extensively. This decline prompted a major review of the National Cervical Screening Program and new clinical management guidelines, for which we undertook this analysis. METHODS: We did effectiveness modelling and an economic assessment of potential new screening strategies, using a model of HPV transmission, vaccination, natural history, and cervical screening. First, we evaluated 132 screening strategies, including those based on cytology and primary HPV testing. Second, after a recommendation was made to adopt primary HPV screening with partial genotyping and direct referral to colposcopy of women positive for HPV16/18, we evaluated the final effect of HPV screening after incorporating new clinical guidelines for women positive for HPV. Both evaluations considered both unvaccinated and vaccinated cohorts. FINDINGS: Strategies entailing HPV testing every 5 years and either partial genotyping for HPV16/18 or cytological co-testing were the most effective. One of the most effective and cost-effective strategies comprised primary HPV screening with referral of women positive for oncogenic HPV16/18 direct to colposcopy, with reflex cytological triage for women with other oncogenic types and direct referral for those in this group with high-grade cytological findings. After incorporating detailed clinical guidelines recommendations, this strategy is predicted to reduce cervical cancer incidence and mortality by 31% and 36%, respectively, in unvaccinated cohorts, and by 24% and 29%, respectively, in cohorts offered vaccination. Furthermore, this strategy is predicted to reduce costs by up to 19% for unvaccinated cohorts and 26% for cohorts offered vaccination, compared with the current programme. INTERPRETATION: Primary HPV screening every 5 years with partial genotyping is predicted to be substantially more effective and potentially cost-saving compared with the current cytology-based screening programme undertaken every 2 years. These findings underpin the decision to transition to primary HPV screening with partial genotyping in the Australian National Cervical Screening Program, which will occur in May, 2017. FUNDING: Department of Health, Australia.
引用
- Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017. PMID: 29253402. doi:10.1016/S2468-2667(17)30007-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。